Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) CEO Sanjiv Patel sold 14,000 shares of Relay Therapeutics stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $23.47, for a total value of $328,580.00. Following the transaction, the chief executive officer now owns 254,554 shares in the company, valued at approximately $5,974,382.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Relay Therapeutics Trading Down 6.6 %
Shares of NASDAQ:RLAY opened at $23.42 on Friday. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -9.15 and a beta of 1.24. The business has a 50-day moving average price of $21.95 and a 200 day moving average price of $22.28. Relay Therapeutics, Inc. has a 12-month low of $12.65 and a 12-month high of $38.15.
Wall Street Analyst Weigh In
RLAY has been the topic of several analyst reports. JMP Securities lifted their price target on Relay Therapeutics from $35.00 to $38.00 and gave the stock a “market outperform” rating in a report on Wednesday. The Goldman Sachs Group reduced their price target on Relay Therapeutics from $49.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, May 24th. Stifel Nicolaus initiated coverage on Relay Therapeutics in a report on Thursday, September 1st. They set a “buy” rating and a $40.00 price target on the stock. HC Wainwright raised their price objective on Relay Therapeutics from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Finally, Jefferies Financial Group initiated coverage on Relay Therapeutics in a research report on Monday, June 6th. They set an “underperform” rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.50.
Hedge Funds Weigh In On Relay Therapeutics
Relay Therapeutics Company Profile
Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.
- Get a free copy of the StockNews.com research report on Relay Therapeutics (RLAY)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.